Person:
BİRCAN, HACI AHMET

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HACI AHMET
Last Name
BİRCAN
Name
Email Address
Birth Date

Filters

2010 - 20178
Reset filters

Settings

Author: AKKAYA, Ahmet ×

Search Results

Now showing 1 - 8 of 8
  • No Thumbnail Available
    PublicationMetadata only
    Respiratory Symptoms, Pulmonary Function, and Reproductive History: Isparta Menopause and Health Study
    (2010-06-01T00:00:00Z) Songur, Necla; AYDIN, Zeynep Dilek; ÖZTÜRK, Önder; Sahin, Unal; Khayri, Ulugbik; Bircan, Ahmet; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    Objective: We aimed to investigate the influence of reproductive factors on chronic respiratory symptoms and pulmonary function in a cross-sectional study of premenopausal and postmenopausal women 44-61 years of age.
  • No Thumbnail Available
    PublicationMetadata only
    The diagnostic significance of signal peptide-complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein-1 levels in pulmonary embolism
    (2016-10-01T00:00:00Z) Dirican, Nigar; Duman, Ali; Saglam, Gulcan; Arslan, Akif; ÖZTÜRK, Önder; Atalay, Sule; Bircan, Ahmet; AKKAYA, Ahmet; ÇAKIR, Münire; BİRCAN, HACI AHMET
    BACKGROUND: Pulmonary embolism (PE) is a common and potentially life-threatening disorder. Patients with PE often have nonspecific symptoms, and the diagnosis is often delayed.
  • No Thumbnail Available
    PublicationMetadata only
    Thiol/disulfide homeostasis: A prognostic biomarker for patients with advanced non-small cell lung cancer?
    (2016-01-01T00:00:00Z) Dirican, Nigar; Dirican, Ahmet; Sen, Orhan; Aynali, Ayse; Atalay, Sule; BİRCAN, HACI AHMET; ÖZTÜRK, Önder; Erdogan, Serpil; ÇAKIR, Münire; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    Background: The aim of this study was to investigate oxidative stress and thiol/disulfide status with a novel automated homeostasis assay in advanced non-small cell lung cancer ( NSCLC).
  • No Thumbnail Available
    PublicationMetadata only
    Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Diagnosis of Pulmonary Embolism
    (2017-01-01T00:00:00Z) Dirican, Nigar; Aynali, Ayse; ÇAKIR, Münire; Atalay, Sule; BİRCAN, HACI AHMET; ÖZTÜRK, Önder; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    Aim: The goal of our study was to compare the suPAR levels between pulmonary embolism (PE) patients and healthy subjects and also to investigate the value of suPAR in the diagnosis of PE. Material and Method: Thirty patients diagnosed with acute PE using spiral computerized tomographic pulmonary angiography were included in the study. suPAR and D-dimer levels were measured at the time of diagnosis. Twenty-nine age-and sex-matched healthy subjects were chosen for the study. The suPARnostic ELISA Standard Kit (ViroGates A/S, Birkerod, Denmark, Code No. A001) was used for the quantitative determination of suPAR levels in plasma samples. Results: Median (95% CI) suPAR level measured in the PE group was 6.4 (6.4-10.5) ng/mL, compared to 3.3 (2.9-4.2) ng/mL in the control group (P< 0.001). suPAR levels were significantly higher in the patients with PE than in controls (P< 0.001). Receiver operator characteristic (ROC) curve analysis was found as 0.871 [confidence interval (CI) 0.776-0.965] area under the curve, 83% specificity, and 82% sensitivity at the cut-off of suPAR. Patients with higher suPAR (4.3 ng/ml) had significantly longer hospital stays than patients with lower suPAR (p= 0.049). There was a statistically significant positive correlation between D-dimer and suPAR (r= 0.530, P= 0.004). Discussion: This study suggests that suPAR may be a biomarker with good sensitivity and specificity for diagnosis of PE. However, large prospective studies are required to demonstrate the diagnostic and prognostic significance of suPAR in PE.
  • No Thumbnail Available
    PublicationMetadata only
    Effects on prognosis of hematologic parameters in patients with small cell lung cancer
    (2016-01-01T00:00:00Z) Dirican, Nigar; Anar, Ceyda; Atalay, Sule; ÖZTÜRK, Önder; BİRCAN, HACI AHMET; ÇAKIR, Münire; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    Purpose: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are prognostic factors for various types of cancer. In this study, we assessed the association of NLR and PLR with the prognosis of small-cell lung cancer (SCLC) in patients who received the standard treatment.
  • No Thumbnail Available
    PublicationMetadata only
    The attitude toward tobacco dependence and barriers to discussing smoking cessation: a survey among Turkish general practitioners
    (2010-06-01T00:00:00Z) Gokirmak, Munire; ÖZTÜRK, Önder; Bircan, Ahmet; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    To evaluate the general attitude of a sample of Turkish general practitioners (GPs) toward tobacco dependence and to assess their knowledge and behavior regarding smoking cessation (SC).
  • No Thumbnail Available
    PublicationMetadata only
    Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters
    (2010-12-01T00:00:00Z) Bircan, Ahmet; BİRCAN, Sema; Kapucuoglu, Nilgun; Songur, Necla; ÖZTÜRK, Önder; AKKAYA, Ahmet; BİRCAN, HACI AHMET
    Maspin, one of the serine protease inhibitors, has been shown to inhibit tumor progression and metastasis. We aimed to investigate maspin, p53 and VEGF expression in patients with squamous cell carcinoma (SCC), adenocarcinoma (AC) and small cell lung carcinoma (SCLC). The study included 28 SCC, 18 AC, 17 SCLC biopsy samples. We used the streptavidin biotin immunoperoxidase method to test for maspin, p53 and VEGF antibodies. Medical records of these patients were reviewed from archival files. Cytoplasmic maspin expression was detected in 89.3%, 77.8%, 52.9% of SCC, AC and SCLC, respectively. The rate was significantly higher in non-small cell lung cancer (NSCLC) and SCC than SCLC (p=0.013,p= 0.021, respectively). The mean percentages of maspin expression were significantly higher in NSCLC, SCC and AC than in SCLC (p=0.000 I, p=0.000 I, p=0.038, respectively). In ACs, maspin and p53 expressions were correlated, although this was not statistically significant (p=0.053, r= 0.464), and maspin positive cases had a significantly higher T status compared to negative cases (p=0.036). In SCC, the stage of disease was positively correlated with p53 (p= 0.007, r=0.536) and negatively correlated with VEGF expression (p=0.013, r=-0.498). Multivariate analysis demonstrated that stage of disease was a significant independent prognostic parameter in NSCLC (95% confidence interval: 1.067-3.969; p=0.031). Although maspin expression is higher in SCC and AC, and is related with higher T status in AC, our data did not indicate its prognostic significance. Larger scale studies are needed to reveal the exact role of maspin in lung cancer pathogenesis.
  • No Thumbnail Available
    PublicationMetadata only
    A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases
    (2016-01-01T00:00:00Z) Dirican, Nigar; Dirican, Ahmet; Anar, Ceyda; Atalay, Sule; ÖZTÜRK, Önder; Bircan, Ahmet; AKKAYA, Ahmet; ÇAKIR, Münire; BİRCAN, HACI AHMET
    Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p < 0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P < 0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice.